Pharmacoeconomics of antiviral therapies for Herpes zoster infections

References

• Ragozzino MW Melton LI Kurland LT et al Population based study of Herpes zoster and its sequelae. Medicine 61,310–316 (1982).
   Google Scholar
• Whitley RJ, Gnann JW. Herpes zoster: focus on treatment in older adults. Antiviral Res 44,145–154 (1999).
   PubMedGoogle Scholar
• Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment and prevention. N Engl Med 335,32–42 (1996).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive clinical review withevidence-based treatment guidelines.
   Google Scholar
• Gilden DH. Herpes zoster with postherpetic neuralgia: persisting pain and frustration. N Engif Med 330, 932–934 (1994).
   PubMed Web of Science ®Google Scholar
• Straus SE. Shingles: sorrows, salves and solutions. JAMA 269,1836–1839 (1993).
   PubMedGoogle Scholar
• Dworkin PH. Prevention of postherpetic neuralgia. Lancet 353, 1636–1637 (1999).
   PubMed Web of Science ®Google Scholar
• McKendrick MW, McGill JI, White JE et al. Oral acyclovir in acute Herpes zoster. Br. Medj 293, 1529–1532 (1986).
   PubMed Web of Science ®Google Scholar
• Wood MJ, Ogan PH, McKendrick MW et al. Efficacy of oral acyclovir treatment of acute Herpes zoster. Am J. Med. 85, 79–83 (1988).
   PubMed Web of Science ®Google Scholar
• Huff JC, Bean B, Balfour III I et al. Therapy of Herpes zoster with oral acyclovir. Am. .j Meal 85,84–89 (1988).
   Google Scholar
• Morton P, Thomson AN. Oral acyclovir in the treatment of Herpes zoster in general practice. NZ Med. 102, 93–95 (1989).
   PubMed Web of Science ®Google Scholar
• Wood MJ, Johnson RVV, McKendrick MW et al. A randomized trial of acyclovir for 7 or 21 days with and without prednisone for treatment of acute Herpes zoster. N Engl. J. Med 330, 896–900 (1994).
   Google Scholar
• Whitley RJ, Weiss H, Gnann JW et al. Acydovir with and without prednisone for treatment of acute Herpes zoster: a randomized placebo-controlled trial. Ann. Intern. Med. 125,376–383 (1996).
   PubMed Web of Science ®Google Scholar
• Tyring S, Barbarash RA, Nahlik JE et al. Famciclovir for the treatment of acute Herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind placebo-controlled trial. Ann. Intern. Med 123, 89–96 (1995).
   PubMed Web of Science ®Google Scholar
• Degreef H. Famcidovir, a new oral antiherpes drug: results of the first controlled clinical study demonstration its efficacy and safety in the treatment of uncomplicated Herpes zoster in immunocompetent patients. Int. J. Antimicrob. Agents 4, 241–246 (1995).
   Google Scholar
• Beutner KR, Friedmena DJ, Forszpaniak C et al. Valacidovir compared with acyclovir for improved therapy of Herpes zoster in immunocompetent adults. Antimicmb. Agents Chemother. 39, 1546–1553 (1995).
   PubMed Web of Science ®Google Scholar
• Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for Herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch. Family Meal 9, 863–869 (2000).
   Google Scholar
• •Well carried out trial showing equal effectiveness of valacyclovir and famciclovir.
   Google Scholar
• Tyring S, Engst R, Corriveau C et al. Famcidovir for ophthalmic zoster: a randomized controlled study. Br. J. Ophthal 85,576–581 (2001).
   PubMed Web of Science ®Google Scholar
• Lin WR, Lin HH, Lee SS et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of Herpes zoster. J. Microbiol Immunol Infect. 34, 138–142 (2001).
   PubMedGoogle Scholar
• Schmader KE, Studenski S. Are current therapies useful for the prevention of postherpetic neuralgia?' Gen. Intern. Med. 4, 83–89 (1989).
   Google Scholar
• Silagy C, Gray S. Primary care management of acute Herpes zoster: systematic review of evidence from randomized controlled trials. Br. J. Gen. Pract. 45, 39–45 (1995).
   PubMedGoogle Scholar
• Crooks RJ, Jones DA, Fiddian AR Zoster- associated chronic pain: an overview of clinical trials with acyclovir. Land. j Infect. DA. Suppl. 80, 62–68 (1991).
   PubMedGoogle Scholar
• Wood MJ, Kay R, Dworkin PH et al Oral acyclovir therapy accelerates pain resolution in patients with Herpes zoster: a meta-analysis of placebo-controlled trials. Clin. Infect. Dis. 22, 341–347 (1996).
   PubMed Web of Science ®Google Scholar
• Jackson JL, Gibbons R, Meyer Get al The effect of treating Herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch. Intern. Med 157, 909–912 (1997).
   PubMed Web of Science ®Google Scholar
• ••Critical of prior meta-analyses thatincluded studies that used insufficient acyclovir dosages.
   Google Scholar
• Johnson R, Mandal B, Bowsher D et al. Guidelines for the management of shingles: report of a working group of the British Society for the Study of Infection. j Infect. 30, 193–200 (1995).
   PubMedGoogle Scholar
• •Clinical guidelines for antiviral therapy of zoster.
   Google Scholar
• Smith KJ, Roberts MS. Antiviral therapies for Herpes zoster infections: are they economically justifiable? PharmacoEconomics 18, 95–104 (2000).
   PubMedGoogle Scholar
• Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents: is the evidence spotty?" Infect. Dis. 178 (Suppl. 1), S85-90 (1998).
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC (Frls). Cost-effectiveness in health and medicine. Oxford University Press, New York, USA (1996).
   Google Scholar
• United States Bureau of Labor Statistics website, stats.b1s.gov. Average hourly wage of production workers, seasonally adjusted, July 2001.
   Google Scholar
• Davies L, Cossins L, Bowsher D, Drummond M. The cost of treatment for post-herpetic neuralgia in the UK. PhannacoEconomics 6, 142–148 (1994). Most rigorous study of the costs of PHN.
   Google Scholar
• Paul JE, Mauskopf JA, Bell L. Cost- consequence models for Varicella-zoster virus infections. Phannacotherapy15, 49S-58S (1995).
   Google Scholar
• Grant DM, Mauskopf JA, Bell L, Austin R. Comparison of valaciclovir and acyclovir for the treatment of Herpes zoster in immunocompetent patients over 50 years of age: a cost-consequence model. Phannacotherapy17, 333–341 (1997).
   PubMed Web of Science ®Google Scholar
• Gruger J, Backhouse ME. Economic evaluation of antiviral therapy for the treatment of Herpes zoster in immunocompetent adults. PhannacoEconomics11, 262–273 (1997).
   PubMedGoogle Scholar
• Huse DM, Schainbaum S, Kirsch AJ, Tyring S. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. Am J. Health-System Pharm. 54, 1180–1184 (1997).
   PubMed Web of Science ®Google Scholar
• Kubeyinje ER Cost-benefit of oral acyclovir in the treatment of Herpes zoster. Lit. J. Dermatology36, 457–459 (1997).
   Google Scholar
• Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med. Care 34, 778–792 (1998).
   Google Scholar
• Fryback DG, Dasbach EJ, Klein R et al. The Beaver Dam health outcomes study: initial catalog of health-state quality factors. Med Decis. Making 13, 89–102 (1993).
   PubMed Web of Science ®Google Scholar
• Drug Topics Red Book. Medical Economics Co. Montvale, NJ, USA (2001).
   Google Scholar
• Mark DB, Hlatky MA, Califf PM et al. Cost effectiveness of thrombotic therapy with tissue plasminogen activator as compared with streptokinase of acute myocarclial infarction. N. Engl. Med 332, 1418–1424 (1995).
   PubMed Web of Science ®Google Scholar
• Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicmb. Agents Chemother. 45, 2771–2774 (2001).
   PubMedGoogle Scholar
• •Small, but important study showing no efficacy in already established PHN.
   Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost- effectiveness acceptability curves. Health Econ. 10, 779–787 (2001).
   PubMed Web of Science ®Google Scholar
• Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of Herpes zoster: prospective study with long-term follow-up. Br. Med. J. 321, 794–796 (2000).
   PubMed Web of Science ®Google Scholar
• •Shows a remarkably low rate of PHN in Iceland, calling into question the usefulness of antivirals in this and other low-prevalence populations.
   Google Scholar
• Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J. Infect. DA 179, 9–15 (1999).
   PubMedGoogle Scholar
• •Outlines patient characteristics that predict worse outcomes, for whom antiviral treatment may be of greatest benefit.
   Google Scholar
• Dworkin PH, Nagasako EM, Johnson RW, Griffin DR. Acute pain in Herpes zoster: the famciclovir database project. Pain 94, 113–119 (2001).
   PubMed Web of Science ®Google Scholar
• Breuer J. Vaccination to prevent varicella and shingles. J. Clin. Pathol 54, 743–747 (2001).
   PubMed Web of Science ®Google Scholar
• Rothberg M, Bennish ML, Kao JS, Wong JB. Do the benefits of varicella vaccination outweigh the long-term risks? A decision-analytic model for policymakers and pediatricians. Clin. Infect. DA. 34, 885–894 (2002).
   PubMedGoogle Scholar
• Kotani N, Kushikata T, Hashimoto H et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl Med 343, 1514–1519 (2000).
   PubMed Web of Science ®Google Scholar